China–India pharmaceutical industry cooperation in the context of “One Belt, One Road”: Opportunities, challenges, and the way forward

Author:

Farooq Muhammad Sabil1ORCID,Nazia Feroze2,Iftikhar Adeel3,Chun Cheng Tong2

Affiliation:

1. Nankai University, China; University of the Poonch Rawalakot, Pakistan

2. Nankai University, China

3. University of the Poonch Rawalakot, Pakistan

Abstract

To promote the “Belt and Road Initiative” (BRI) in India, it is necessary to highlight the economic attributes, highlight the role of the market, cultivate new growth points of cooperation, and consolidate the foundation of common interests. Industrial cooperation is an important part not only of the “Belt and Road” construction, but also of economic cooperation between the countries. The pharmaceutical product industry is India's most advantageous industry, and it is also an industry with which India hopes to strengthen cooperation with China. In the context of “One Belt, One Road,” China–India pharmaceutical industry cooperation faces both rare opportunities and some challenges, but from the perspective of development trends, obstacles are gradually reducing. Promoting Sino–Indian pharmaceutical industry cooperation requires the joint efforts of government departments, industry chambers of commerce, and pharmaceutical companies. The key is to choose the right cooperation field and path. Strengthening China–India pharmaceutical industry cooperation is conducive to fostering new growth points for China–India economic cooperation, reducing India's concerns about the BRI, and promoting the BRI in India and the entire South Asian region.

Publisher

SAGE Publications

Subject

Political Science and International Relations,Sociology and Political Science

Reference28 articles.

1. Department of Pharmaceuticals (2016–2017) Ministry of Chemicals and Fertilizers: Annual report 2016–2017. Available at: http://pharmaceuticals.gov.in/sites/default/files/Chemical%20Pharma%20-2016-17%20English%20Final%20%20for%20mail%20%282%29.Pdf (accessed xxxx).

2. Pharmaceuticals Export Promotion Council of India (2017) Annual report,2016-2017.

3. The Pharmaceutical Industry in India after TRIPS

4. Chen L (2006) The reason and enlightenment of the rise of Indian pharmaceutical industry: Yunnan Social Sciences 05(16).

5. Chen YC (2012) India’s patent laws protection and enlightenment for its pharmaceutical industry: Jiangsu Science and Technology Information 14 (11).

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3